Tempest Therapeutics, Inc. Cash And Cash Equivalents At Carrying Value

• Tempest Therapeutics, Inc. showed a decrease of -74.5% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
• This data is from Tempest Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
• XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q4 2010: $0.00 | Q2 2011: $7.0 thousand | Q3 2011: $5.59 million | Q2 2012: $34.07 million | Q3 2012: $35.12 million | Q1 2013: $43.19 million | Q2 2013: $28.19 million | Q3 2013: $21.08 million | Q1 2014: $56.13 million | Q2 2014: $16.55 million | Q3 2014: $12.13 million | Q1 2015: $134.70 million | Q2 2015: $70.24 million | Q3 2015: $50.84 million | Q1 2016: $20.48 million | Q2 2016: $95.89 million | Q3 2016: $50.48 million | Q1 2017: $25.43 million | Q2 2017: $22.94 million | Q3 2017: $24.78 million | Q1 2018: $19.72 million | Q2 2018: $24.60 million | Q3 2018: $31.92 million | Q1 2019: $65.59 million | Q2 2019: $55.27 million | Q3 2019: $47.15 million | Q1 2020: $58.01 million | Q2 2020: $50.31 million | Q3 2020: $18.82 million | Q1 2021: $51.83 million | Q2 2021: $68.41 million | Q3 2021: $59.72 million | Q1 2022: $45.75 million | Q2 2022: $51.62 million | Q3 2022: $42.79 million | Q1 2023: $22.93 million | Q2 2023: $17.60 million | Q3 2023: $11.12 million | Q1 2024: $32.33 million | Q2 2024: $31.12 million | Q3 2024: $22.12 million | Q1 2025: $21.51 million | Q2 2025: $14.28 million | Q3 2025: $7.51 million.
• Over the full 15 years of available data (2011 to 2025), Tempest Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 69.7%.
• Historical annual values: Fiscal year 2025: $7.71 million | Fiscal year 2024: $30.27 million | Fiscal year 2023: $39.23 million | Fiscal year 2022: $31.23 million | Fiscal year 2021: $51.83 million | Fiscal year 2020: $18.82 million | Fiscal year 2019: $62.48 million | Fiscal year 2018: $73.29 million | Fiscal year 2017: $17.58 million | Fiscal year 2016: $43.93 million | Fiscal year 2015: $43.22 million | Fiscal year 2014: $6.41 million | Fiscal year 2013: $18.08 million | Fiscal year 2012: $14.78 million | Fiscal year 2011: $4.54 million.
• Data sourced from SEC EDGAR public filings as of August 10, 2026.

Last verified: August 10, 2026